These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 30682240)

  • 1. Engineering of Bone- and CD44-Dual-Targeting Redox-Sensitive Liposomes for the Treatment of Orthotopic Osteosarcoma.
    Feng S; Wu ZX; Zhao Z; Liu J; Sun K; Guo C; Wang H; Wu Z
    ACS Appl Mater Interfaces; 2019 Feb; 11(7):7357-7368. PubMed ID: 30682240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models.
    Chi Y; Yin X; Sun K; Feng S; Liu J; Chen D; Guo C; Wu Z
    J Control Release; 2017 Sep; 261():113-125. PubMed ID: 28666726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma.
    Yin X; Feng S; Chi Y; Liu J; Sun K; Guo C; Wu Z
    Drug Deliv; 2018 Nov; 25(1):900-908. PubMed ID: 29644882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.
    Gazzano E; Buondonno I; Marengo A; Rolando B; Chegaev K; Kopecka J; Saponara S; Sorge M; Hattinger CM; Gasco A; Fruttero R; Brancaccio M; Serra M; Stella B; Fattal E; Arpicco S; Riganti C
    Cancer Lett; 2019 Aug; 456():29-39. PubMed ID: 31047947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction-sensitive CD44 receptor-targeted hyaluronic acid derivative micelles for doxorubicin delivery.
    Yang Y; Zhao Y; Lan J; Kang Y; Zhang T; Ding Y; Zhang X; Lu L
    Int J Nanomedicine; 2018; 13():4361-4378. PubMed ID: 30100720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual targeting curcumin loaded alendronate-hyaluronan- octadecanoic acid micelles for improving osteosarcoma therapy.
    Xi Y; Jiang T; Yu Y; Yu J; Xue M; Xu N; Wen J; Wang W; He H; Shen Y; Chen D; Ye X; Webster TJ
    Int J Nanomedicine; 2019; 14():6425-6437. PubMed ID: 31496695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coadministration of Oligomeric Hyaluronic Acid-Modified Liposomes with Tumor-Penetrating Peptide-iRGD Enhances the Antitumor Efficacy of Doxorubicin against Melanoma.
    Deng C; Zhang Q; Fu Y; Sun X; Gong T; Zhang Z
    ACS Appl Mater Interfaces; 2017 Jan; 9(2):1280-1292. PubMed ID: 28009503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytarabine delivered by CD44 and bone targeting redox-sensitive liposomes for treatment of acute myelogenous leukemia.
    Wu H; Gao Y; Ma J; Hu M; Xia J; Bao S; Liu Y; Feng K
    Regen Biomater; 2022; 9():rbac058. PubMed ID: 36110161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low molecular weight heparin modified bone targeting liposomes for orthotopic osteosarcoma and breast cancer bone metastatic tumors.
    Wu H; Luo Y; Xu D; Ke X; Ci T
    Int J Biol Macromol; 2020 Dec; 164():2583-2597. PubMed ID: 32795579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chitooligosaccharides Modified Reduction-Sensitive Liposomes: Enhanced Cytoplasmic Drug Delivery and Osteosarcomas-Tumor Inhibition in Animal Models.
    Yin X; Chi Y; Guo C; Feng S; Liu J; Sun K; Wu Z
    Pharm Res; 2017 Oct; 34(10):2172-2184. PubMed ID: 28726003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD44-specific nanoparticles for redox-triggered reactive oxygen species production and doxorubicin release.
    Lin CW; Lu KY; Wang SY; Sung HW; Mi FL
    Acta Biomater; 2016 Apr; 35():280-92. PubMed ID: 26853764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxorubicin-poly (ethylene glycol)-alendronate self-assembled micelles for targeted therapy of bone metastatic cancer.
    Ye WL; Zhao YP; Li HQ; Na R; Li F; Mei QB; Zhao MG; Zhou SY
    Sci Rep; 2015 Sep; 5():14614. PubMed ID: 26419507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Actively targeted delivery of doxorubicin to bone metastases by a pH-sensitive conjugation.
    Ye WL; Zhao YP; Na R; Li F; Mei QB; Zhao MG; Zhou SY
    J Pharm Sci; 2015 Jul; 104(7):2293-303. PubMed ID: 25980534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. pH- and GSH-Sensitive Hyaluronic Acid-MP Conjugate Micelles for Intracellular Delivery of Doxorubicin to Colon Cancer Cells and Cancer Stem Cells.
    Debele TA; Yu LY; Yang CS; Shen YA; Lo CL
    Biomacromolecules; 2018 Sep; 19(9):3725-3737. PubMed ID: 30044910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multifunctional redox-responsive and CD44 receptor targeting polymer-drug nanomedicine based curcumin and alendronate: synthesis, characterization and in vitro evaluation.
    Dong X; Zou S; Guo C; Wang K; Zhao F; Fan H; Yin J; Chen D
    Artif Cells Nanomed Biotechnol; 2018; 46(sup1):168-177. PubMed ID: 29239219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Redox-Responsive and Dual-Targeting Hyaluronic Acid-Methotrexate Prodrug Self-Assembling Nanoparticles for Enhancing Intracellular Drug Self-Delivery.
    Zhang Y; Li Y; Tian H; Zhu Q; Wang F; Fan Z; Zhou S; Wang X; Xie L; Hou Z
    Mol Pharm; 2019 Jul; 16(7):3133-3144. PubMed ID: 31198046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
    Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
    J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms.
    Clementi C; Miller K; Mero A; Satchi-Fainaro R; Pasut G
    Mol Pharm; 2011 Aug; 8(4):1063-72. PubMed ID: 21608527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonate-functionalized coordination polymer nanoparticles for the treatment of bone metastatic breast cancer.
    He Y; Huang Y; Huang Z; Jiang Y; Sun X; Shen Y; Chu W; Zhao C
    J Control Release; 2017 Oct; 264():76-88. PubMed ID: 28842315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vivo Evaluation of Reduction-Responsive Alendronate-Hyaluronan-Curcumin Polymer-Drug Conjugates for Targeted Therapy of Bone Metastatic Breast Cancer.
    Wang K; Guo C; Dong X; Yu Y; Wang B; Liu W; Chen D
    Mol Pharm; 2018 Jul; 15(7):2764-2769. PubMed ID: 29792799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.